Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report

Bruce Shiramizu; Stanton Goldman; Lynette Smith; Melissa Agsalda-Garcia; Paul Galardy; Sherrie L. Perkins; J. Kimble Frazer; Warren Sanger; James R. Anderson; Thomas G. Gross; Howard Weinstein; Lauren Harrison; Matthew J. Barth; Lara Mussolin; Mitchell S. Cairo

doi:10.1111/bjh.13443

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report

Bruce Shiramizu, Stanton Goldman, Lynette Smith, Melissa Agsalda-Garcia, Paul Galardy, Sherrie L. Perkins, J. Kimble Frazer, Warren Sanger, James R. Anderson, Thomas G. Gross, Howard Weinstein, Lauren Harrison, Matthew J. Barth, Lara Mussolin, Mitchell S. Cairo

Pediatric and Adolescent Medicine

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

Original language	English (US)
Pages (from-to)	367-371
Number of pages	5
Journal	British journal of haematology
Volume	170
Issue number	3
DOIs	https://doi.org/10.1111/bjh.13443
State	Published - 2015

Keywords

central nervous system
children
leukaemia

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.13443

Cite this

Shiramizu, B., Goldman, S., Smith, L., Agsalda-Garcia, M., Galardy, P., Perkins, S. L., Frazer, J. K., Sanger, W., Anderson, J. R., Gross, T. G., Weinstein, H., Harrison, L., Barth, M. J., Mussolin, L., & Cairo, M. S. (2015). Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. British journal of haematology, 170(3), 367-371. https://doi.org/10.1111/bjh.13443

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. / Shiramizu, Bruce; Goldman, Stanton; Smith, Lynette et al.
In: British journal of haematology, Vol. 170, No. 3, 2015, p. 367-371.

Research output: Contribution to journal › Article › peer-review

Shiramizu, B, Goldman, S, Smith, L, Agsalda-Garcia, M, Galardy, P, Perkins, SL, Frazer, JK, Sanger, W, Anderson, JR, Gross, TG, Weinstein, H, Harrison, L, Barth, MJ, Mussolin, L & Cairo, MS 2015, 'Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report', British journal of haematology, vol. 170, no. 3, pp. 367-371. https://doi.org/10.1111/bjh.13443

@article{85a4fef76cab49b8853a4f76f33d9eaa,

title = "Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report",

abstract = "Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.",

keywords = "central nervous system, children, leukaemia",

author = "Bruce Shiramizu and Stanton Goldman and Lynette Smith and Melissa Agsalda-Garcia and Paul Galardy and Perkins, {Sherrie L.} and Frazer, {J. Kimble} and Warren Sanger and Anderson, {James R.} and Gross, {Thomas G.} and Howard Weinstein and Lauren Harrison and Barth, {Matthew J.} and Lara Mussolin and Cairo, {Mitchell S.}",

note = "Publisher Copyright: {\textcopyright} 2015 John Wiley & Sons Ltd",

year = "2015",

doi = "10.1111/bjh.13443",

language = "English (US)",

volume = "170",

pages = "367--371",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia

T2 - a Children's Oncology Group Pilot Study Report

AU - Shiramizu, Bruce

AU - Goldman, Stanton

AU - Smith, Lynette

AU - Agsalda-Garcia, Melissa

AU - Galardy, Paul

AU - Perkins, Sherrie L.

AU - Frazer, J. Kimble

AU - Sanger, Warren

AU - Anderson, James R.

AU - Gross, Thomas G.

AU - Weinstein, Howard

AU - Harrison, Lauren

AU - Barth, Matthew J.

AU - Mussolin, Lara

AU - Cairo, Mitchell S.

PY - 2015

Y1 - 2015

N2 - Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

AB - Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

KW - central nervous system

KW - children

KW - leukaemia

UR - http://www.scopus.com/inward/record.url?scp=84964696036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964696036&partnerID=8YFLogxK

U2 - 10.1111/bjh.13443

DO - 10.1111/bjh.13443

M3 - Article

C2 - 25858645

AN - SCOPUS:84964696036

SN - 0007-1048

VL - 170

SP - 367

EP - 371

JO - British journal of haematology

JF - British journal of haematology

IS - 3

ER -

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this